- World rank, 2022–2025
- #6,661 of 28,054 · #11,360 all time
- Rank in Germany
- #279 of 1,178
- Research works
- 161 ▲ 128% vs 2013–17
- Citations
- 8.8k 54.3 per fractional work
- Top-10% rate
- 38.2% record average 16.5%
- Open access
- 69% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 13.4×. Every wedge is a field page.
- Immunology and Microbiology 13.4×
- Biochemistry, Genetics and Molecular Biology 4.6×
- Pharmacology, Toxicology and Pharmaceutics 3.6×
- Medicine 2.4×
- Decision Sciences 1.3×
- Agricultural and Biological Sciences 0.6×
- Chemistry 0.4×
- Neuroscience 0.4×
- Materials Science 0.4×
- Social Sciences 0.3×
- Mathematics 0.3×
- Computer Science 0.2×
- Dentistry 0.2×
- Environmental Science 0.1×
- Physics and Astronomy 0.1×
- Psychology 0.1×
- Economics, Econometrics and Finance 0.1×
- Engineering 0.1×
- Health Professions 0.1×
- Business, Management and Accounting 0.1×
- Earth and Planetary Sciences 0.0×
Who are the top researchers at BioNTech (Germany)?
Ranked on the composite score, Uğur Şahin, Evelyna Derhovanessian and Alexander Muik lead among researchers whose main affiliation is BioNTech (Germany).
- 1 Uğur Şahin Germany · #10,728 worldwide 1k citations · 105 works
- 2 Evelyna Derhovanessian Germany · #215,860 worldwide 177 citations · 24 works
- 3 Alexander Muik Germany · #540,143 worldwide 88 citations · 17 works
- 4 Federico Mensa Germany · #1,222,354 worldwide 5 citations · 17 works
Which keywords describe research at BioNTech (Germany)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunity, Vaccine, SARS-CoV-2, Pandemic, Coronavirus, Cancer Immunotherapy, ACE2 Receptor and Antigen Presentation.
- Targeted Therapy
- Norovirus
- Peptide-MHC Binding
- Epitope Prediction
- Fc Receptors
- Chimeric Antigen Receptor
- Therapeutic Antibodies
- Monoclonal Antibodies
- RNA Interference
- Immune Checkpoint Blockade
- Tumor Regression
- Tumor Antigen
- Pathogenesis
- Innate Immunity
- spike protein
- Viral Transmission
- Epidemiology
- Cancer Immunotherapy
- Pandemic
- Vaccine
- Immunity
- SARS-CoV-2
- Coronavirus
- ACE2 Receptor
- Antigen Presentation
- antibody
- Gene Therapy
- Immunotherapy
- Dendritic Cells
- Tumor Microenvironment
- Immune Response
- PD-1 and PD-L1
- siRNA Delivery
- Glycosylation
- CAR T Cells
- Antibody Engineering
- COVID-19 Vaccine
- Infection
- Vaccine Hesitancy
- Rotavirus
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Immunity11▲ 39×4 topics
- Vaccine11▲ 38×8 topics
- SARS-CoV-29▲ 38×5 topics
- Pandemic8▲ 11×5 topics
- Coronavirus8▲ 54×2 topics
- Cancer Immunotherapy8▲ 70×2 topics
- ACE2 Receptor7▲ 44×2 topics
- Epidemiology7▲ 2.7×23 topics
- Antigen Presentation6▲ 106×2 topics
- Viral Transmission6▲ 62×2 topics
- antibody6▲ 86×1 topic
- spike protein6▲ 86×1 topic
- Gene Therapy6▲ 47×3 topics
- Innate Immunity6▲ 25×6 topics
- Immunotherapy5▲ 10×12 topics
- Pathogenesis5▲ 13×9 topics
- Dendritic Cells4▲ 70×1 topic
- Tumor Antigen4▲ 102×1 topic
- Tumor Microenvironment4▲ 14×6 topics
- Tumor Regression4▲ 54×2 topics
- Immune Response4▲ 10×11 topics
- Immune Checkpoint Blockade4▲ 52×1 topic
- PD-1 and PD-L14▲ 52×1 topic
- RNA Interference4▲ 64×1 topic
- siRNA Delivery4▲ 92×1 topic
- Monoclonal Antibodies4▲ 60×3 topics
- Glycosylation3▲ 44×3 topics
- Therapeutic Antibodies3▲ 68×2 topics
- CAR T Cells3▲ 61×1 topic
- Chimeric Antigen Receptor3▲ 61×1 topic
- Antibody Engineering3▲ 78×1 topic
- Fc Receptors3▲ 78×1 topic
- COVID-19 Vaccine2▲ 41×1 topic
- Epitope Prediction2▲ 114×1 topic
- Infection2▲ 12×2 topics
- Peptide-MHC Binding2▲ 114×1 topic
- Vaccine Hesitancy2▲ 45×1 topic
- Norovirus2▲ 62×1 topic
- Rotavirus2▲ 62×1 topic
- Targeted Therapy2▲ 12×4 topics
Which research topics does BioNTech (Germany) publish most on?
By volume in 2022–2025: SARS-CoV-2 and COVID-19 Research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers and RNA Interference and Gene Delivery.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 SARS-CoV-2 and COVID-19 Research Infectious Diseases 6 works
- 2 Immunotherapy and Immune Responses Immunology 4 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 4 works
- 4 RNA Interference and Gene Delivery Molecular Biology 4 works
- 5 CAR-T cell therapy research Oncology 3 works
- 6 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 3 works
- 7 vaccines and immunoinformatics approaches Molecular Biology 2 works
- 8 Vaccine Coverage and Hesitancy Health 2 works
- 9 Viral gastroenteritis research and epidemiology Infectious Diseases 2 works
- 10 Animal Virus Infections Studies Animal Science and Zoology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has BioNTech (Germany)'s research output changed?
Output in 2018–2022 was 128% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Mainz
- Johannes Gutenberg University Mainz
- University Medical Center of the Johannes Gutenberg University Mainz
- Max Planck Institute for Polymer Research
- University of Applied Sciences Mainz
- University of Koblenz and Landau
- Schott (Germany)
- Max Planck Institute for Chemistry
- Institute of Molecular Biology
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.